Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (30296) 30296
Newsletter (410) 410
Newspaper Article (408) 408
Book Chapter (109) 109
Magazine Article (46) 46
Book / eBook (11) 11
Trade Publication Article (10) 10
Dissertation (4) 4
Web Resource (4) 4
Publication (3) 3
Book Review (1) 1
Reference (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (26498) 26498
science & technology (21613) 21613
life sciences & biomedicine (21218) 21218
male (18228) 18228
cardiovascular system & cardiology (16574) 16574
female (16060) 16060
middle aged (14537) 14537
cardiac & cardiovascular systems (13807) 13807
aged (13610) 13610
treatment outcome (11993) 11993
stents (9389) 9389
angioplasty (8167) 8167
angioplasty, balloon, coronary - adverse effects (7629) 7629
biological and medical sciences (7505) 7505
medical sciences (7443) 7443
time factors (6659) 6659
risk factors (6623) 6623
transluminal angioplasty (6253) 6253
abridged index medicus (6184) 6184
coronary angiography (4995) 4995
coronary heart disease (4573) 4573
peripheral vascular disease (4372) 4372
angioplasty, balloon, coronary (4351) 4351
follow-up studies (4189) 4189
retrospective studies (4081) 4081
cardiology (4043) 4043
angioplasty, balloon - adverse effects (4029) 4029
cardiology. vascular system (4003) 4003
surgery (3968) 3968
aged, 80 and over (3913) 3913
adult (3899) 3899
heart attacks (3892) 3892
risk assessment (3697) 3697
stent (3649) 3649
heart (3487) 3487
prospective studies (3487) 3487
cardiac patients (3426) 3426
percutaneous coronary intervention (3334) 3334
myocardial infarction - therapy (3313) 3313
cardiovascular (3280) 3280
care and treatment (3174) 3174
mortality (3066) 3066
angioplasty, balloon, coronary - instrumentation (2904) 2904
radiotherapy. instrumental treatment. physiotherapy. reeducation. rehabilitation, orthophony, crenotherapy. diet therapy and various other treatments (2847) 2847
recurrence (2710) 2710
coronary artery disease - therapy (2700) 2700
coronary vessels (2689) 2689
coronary disease - therapy (2616) 2616
angioplasty, balloon, coronary - methods (2576) 2576
stents - adverse effects (2576) 2576
diseases of the cardiovascular system (2544) 2544
cardiovascular disease (2498) 2498
drug-eluting stents (2414) 2414
analysis (2337) 2337
cardiology and cardiovascular medicine (2199) 2199
myocardial infarction (2196) 2196
patients (2171) 2171
prosthesis design (2158) 2158
coronary artery bypass (2134) 2134
heart attack (2072) 2072
platelet aggregation inhibitors - therapeutic use (2020) 2020
animals (1931) 1931
prognosis (1843) 1843
myocardial infarction - etiology (1742) 1742
severity of illness index (1728) 1728
angioplasty - adverse effects (1705) 1705
angioplasty, balloon - instrumentation (1680) 1680
thrombosis (1671) 1671
registries (1659) 1659
general & internal medicine (1646) 1646
predictive value of tests (1642) 1642
myocardial infarction - mortality (1628) 1628
electrocardiography (1598) 1598
medicine, general & internal (1531) 1531
vascular patency (1517) 1517
kaplan-meier estimate (1515) 1515
patient outcomes (1496) 1496
percutaneous coronary intervention - adverse effects (1493) 1493
restenosis (1485) 1485
medicine & public health (1472) 1472
angioplasty, balloon, coronary - mortality (1469) 1469
medical research (1469) 1469
coronary artery disease (1458) 1458
research (1452) 1452
health aspects (1439) 1439
cardiovascular diseases (1390) 1390
incidence (1359) 1359
diabetes (1288) 1288
multivariate analysis (1281) 1281
coronary stenosis - therapy (1279) 1279
acute coronary syndromes (1269) 1269
coronary restenosis - etiology (1252) 1252
thrombosis - etiology (1249) 1249
angioplasty, balloon (1245) 1245
ticlopidine - analogs & derivatives (1240) 1240
randomized controlled trials as topic (1226) 1226
angiography (1219) 1219
surgery. transplantations, organ and tissue grafts. graft diseases (1211) 1211
studies (1208) 1208
clinical trials (1193) 1193
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (30077) 30077
German (329) 329
French (308) 308
Japanese (307) 307
Spanish (206) 206
Chinese (153) 153
Russian (135) 135
Italian (126) 126
Portuguese (115) 115
Polish (101) 101
Danish (31) 31
Norwegian (28) 28
Swedish (26) 26
Czech (25) 25
Dutch (24) 24
Turkish (21) 21
Hungarian (19) 19
Hebrew (15) 15
Serbian (12) 12
Bulgarian (6) 6
Croatian (3) 3
Finnish (3) 3
Icelandic (3) 3
Lithuanian (3) 3
Romanian (3) 3
Ukrainian (2) 2
Afrikaans (1) 1
Korean (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
by Mehran, Roxana, Dr and Lansky, Alexandra J, MD and Witzenbichler, Bernhard, MD and Guagliumi, Giulio, MD and Peruga, Jan Z, MD and Brodie, Bruce R, MD and Dudek, Dariusz, MD and Kornowski, Ran, MD and Hartmann, Franz, MD and Gersh, Bernard J, Prof and Pocock, Stuart J, Prof and Wong, S Chiu, MD and Nikolsky, Eugenia, MD and Gambone, Louise, MD and Vandertie, Lynn and Parise, Helen, ScD and Dangas, George D, MD and Stone, Gregg W, Prof and for the HORIZONS-AMI Trial Investigators and HORIZONS-AMI Trial Investigators
The Lancet (British edition), ISSN 0140-6736, 2009, Volume 374, Issue 9696, pp. 1149 - 1159
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recombinant Proteins - therapeutic use | Myocardial Infarction - mortality | Follow-Up Studies | Humans | Middle Aged | Heparin - therapeutic use | Male | Recombinant Proteins - adverse effects | Heparin - adverse effects | Angioplasty, Balloon, Coronary - adverse effects | Aged, 80 and over | Adult | Female | Thrombosis - prevention & control | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Hemorrhage - epidemiology | Kaplan-Meier Estimate | Proportional Hazards Models | Anticoagulants - therapeutic use | Survival Rate | Treatment Outcome | Anticoagulants - adverse effects | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Myocardial Infarction - drug therapy | Thrombosis - etiology | Hirudins - adverse effects | Aged | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Hemorrhage - chemically induced | Stents - adverse effects | Care and treatment | Angioplasty | Patient outcomes | Bivalirudin | Dosage and administration | Health aspects | Heart attack | Clinical trials | Cardiovascular disease | Heart attacks | Drug therapy | Mortality | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis
by Mega, Jessica L and Simon, Tabassome and Collet, Jean-Philippe and Anderson, Jeffrey L and Antman, Elliott M and Bliden, Kevin and Cannon, Christopher P and Danchin, Nicolas and Giusti, Betti and Gurbel, Paul and Horne, Benjamin D and Hulot, Jean-Sebastian and Kastrati, Adnan and Montalescot, Gilles and Neumann, Franz-Josef and Shen, Lei and Sibbing, Dirk and Steg, P. Gabriel and Trenk, Dietmar and Wiviott, Stephen D and Sabatine, Marc S
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 10/2010, Volume 304, Issue 16, pp. 1821 - 1830
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Pharmacogenetics | Thrombosis - chemically induced | Ticlopidine - therapeutic use | Humans | Middle Aged | Aryl Hydrocarbon Hydroxylases - genetics | Genotype | Male | Risk | Treatment Outcome | Ticlopidine - analogs & derivatives | Angioplasty, Balloon, Coronary | Cytochrome P-450 CYP2C19 | Ticlopidine - adverse effects | Ticlopidine - metabolism | Acute Coronary Syndrome - therapy | Female | Cardiovascular Diseases - chemically induced | Platelet Aggregation Inhibitors - metabolism | Platelet Aggregation Inhibitors - therapeutic use | Stents | Platelet Aggregation Inhibitors - adverse effects | Drugs | Angioplasty | Medical treatment | Cardiovascular disease | Patients | Clinical outcomes | Meta-analysis
Journal Article
Details down arrow
3. Full Text Incidence, Prognostic Impact, and Influence of Antithrombotic Therapy on Access and Nonaccess Site Bleeding in Percutaneous Coronary Intervention
by Verheugt, Freek W.A., MD and Steinhubl, Steven R., MD and Hamon, Martial, MD and Darius, Harald, MD, PhD and Steg, Philippe Gabriel, MD and Valgimigli, Marco, MD, PhD and Marso, Steven P., MD and Rao, Sunil V., MD and Gershlick, Anthony H., MD and Lincoff, A. Michael, MD and Mehran, Roxana, MD and Stone, Gregg W., MD
JACC. Cardiovascular interventions, ISSN 1936-8798, 2011, Volume 4, Issue 2, pp. 191 - 197
Cardiovascular | percutaneous coronary intervention | bivalirudin | bleeding | access site | Thrombolysis In Myocardial Infarction (TIMI) | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Risk Assessment | Humans | Middle Aged | Risk Factors | Proportional Hazards Models | Punctures | Hemorrhage - mortality | Male | Recombinant Proteins - adverse effects | Anticoagulants - adverse effects | Heparin - adverse effects | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Randomized Controlled Trials as Topic | Angioplasty, Balloon, Coronary - adverse effects | Fibrinolytic Agents - adverse effects | Angioplasty, Balloon, Coronary - mortality | Time Factors | Hemorrhage - etiology | Hirudins - adverse effects | Female | Aged | Peptide Fragments - adverse effects | Platelet Aggregation Inhibitors - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Bivalirudin during Primary PCI in Acute Myocardial Infarction
by Stone, Gregg W and Witzenbichler, Bernhard and Guagliumi, Giulio and Peruga, Jan Z and Brodie, Bruce R and Dudek, Dariusz and Kornowski, Ran and Hartmann, Franz and Gersh, Bernard J and Pocock, Stuart J and Dangas, George and Wong, S. Chiu and Kirtane, Ajay J and Parise, Helen and Mehran, Roxana and HORIZONS AMI Trial Investigators and HORIZONS-AMI Trial Investigators
The New England journal of medicine, ISSN 0028-4793, 05/2008, Volume 358, Issue 21, pp. 2218 - 2230
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cardiology. Vascular system | Heart | Biological and medical sciences | General aspects | Medical sciences | Coronary heart disease | Recombinant Proteins - therapeutic use | Recurrence | Myocardial Infarction - mortality | Humans | Middle Aged | Heparin - therapeutic use | Male | Recombinant Proteins - adverse effects | Heparin - adverse effects | Angioplasty, Balloon, Coronary | Myocardial Infarction - therapy | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | Antithrombins - therapeutic use | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Thrombosis - epidemiology | Combined Modality Therapy | Anticoagulants - adverse effects | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Myocardial Infarction - complications | Stroke - etiology | Thrombosis - etiology | Antithrombins - adverse effects | Hirudins - adverse effects | Aged | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Hemorrhage - chemically induced | Stents - adverse effects | Care and treatment | Coronary artery bypass | Bivalirudin | Drug therapy, Combination | Heparin | Comparative analysis | Health aspects | Heart attack | Stroke | Heart attacks | Ischemia | Cardiology | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction
by Labos, Christopher and Dasgupta, Kaberi and Nedjar, Hacene and Turecki, Gustavo and Rahme, Elham
Canadian Medical Association journal (CMAJ), ISSN 0820-3946, 11/2011, Volume 183, Issue 16, pp. 1835 - 1843
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Age Factors | Anemia - epidemiology | Angioplasty | Humans | Middle Aged | Citalopram - adverse effects | Male | Risk | Secondary Prevention | Sertraline - adverse effects | Peptic Ulcer - epidemiology | Adrenal Cortex Hormones - therapeutic use | Renal Insufficiency - epidemiology | Aspirin - administration & dosage | Paroxetine - adverse effects | Paroxetine - administration & dosage | Fluvoxamine - administration & dosage | Canada - epidemiology | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Retrospective Studies | Drug Therapy, Combination | Heart Failure - epidemiology | Fluoxetine - adverse effects | Platelet Aggregation Inhibitors - adverse effects | Hypoglycemic Agents - therapeutic use | Hemorrhage - epidemiology | Risk Factors | Serotonin Uptake Inhibitors - adverse effects | Anticoagulants - therapeutic use | Antihypertensive Agents - therapeutic use | Fluvoxamine - adverse effects | Ticlopidine - analogs & derivatives | Citalopram - administration & dosage | Sertraline - administration & dosage | Serotonin Uptake Inhibitors - administration & dosage | Fluoxetine - administration & dosage | Sex Factors | Aged | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Neoplasms - epidemiology | Cohort Studies | Aggregation | Complications and side effects | Blood platelets | Patient outcomes | Serotonin uptake inhibitors | Dosage and administration | Drug therapy | Hemorrhage | Heart attack | Risk factors | Studies | Side effects | Heart attacks | Inhibitor drugs | Index Medicus | Abridged Index Medicus | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome the SECURE-PCI randomized clinical trial
by Berwanger, Otavio and Santucci, Eliana Vieira and De Barros E Silva, Pedro Gabriel Melo and Jesuíno, Isabella De Andrade and Damiani, Lucas Petri and Barbosa, Lilian Mazza and Nakagawa Santos, Renato Hideo and Laranjeira, Ligia Nasi and Egydio, Flávia De Mattos and Borges De Oliveira, Juliana Aparecida and Dall Orto, Frederico Toledo Campo and De Andrade, Pedro Beraldo and De Castro Bienert, Igor Ribeiro and Bosso, Carlos Eduardo and Mangione, José Armando and Polanczyk, Carisi Anne and De Moraes Rego Sousa, Amanda Guerra and Kalil, Renato Abdala Karam and Santos, Luciano De Moura and Sposito, Andrei Carvalho and Rech, Rafael Luiz and Sousa, Antônio Carlos Sobral and Baldissera, Felipe and Nascimento, Bruno Ramos and Giraldez, Roberto Rocha Corrêa Veiga and Cavalcanti, Alexandre Biasi and Pereira, Sabrina Bernardez and Mattos, Luiz Alberto and Armaganijan, Luciana Vidal and Guimarães, Hélio Penna and Rego Sousa, José Eduardo Moraes and Alexander, John Hunter and Granger, Christopher Bull and Lopes, Renato Delascio and De Barros E Silva, Pedro Gabriel Mela and De Macedo, Thiago Andrade and Peixoto De Miranda, Érique José Farias and Godoy, Lucas Colombo and Dos Santos, Marília Harumi Higuchi and Katz, Marcelo and Truffa, Adriano Augusto Meirelles and Carvalho, Leonardo and Oliveira, Roger and Valois, Mayara Vioto and Pacheco, Beatriz Gonzales and Kodama, Alessandra and Sampaio, Bruna and SECURE- PCI Investigators
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 04/2018, Volume 319, Issue 13, pp. 1331 - 1340
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Myocardial infarction | Intervention | Cerebral infarction | Stroke | Angiography | Angioplasty | Coronary artery | Clinical trials | Rhabdomyolysis | Management | Patients | Surgery | Atorvastatin | Infarction | Acute coronary syndromes | Drug dosages | Statins
Journal Article
Details down arrow
7. Full Text Abciximab and Heparin versus Bivalirudin for Non–ST-Elevation Myocardial Infarction
by Kastrati, Adnan and Neumann, Franz-Josef and Schulz, Stefanie and Massberg, Steffen and Byrne, Robert A and Ferenc, Miroslaw and Laugwitz, Karl-Ludwig and Pache, Jürgen and Ott, Ilka and Hausleiter, Jörg and Seyfarth, Melchior and Gick, Michael and Antoniucci, David and Schömig, Albert and Berger, Peter B and Mehilli, Julinda and ISAR-REACt 4 Trial Investigators and ISAR-REACT 4 Trial Investigators
The New England journal of medicine, ISSN 0028-4793, 11/2011, Volume 365, Issue 21, pp. 1980 - 1989
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cardiology. Vascular system | Heart | General aspects | Biological and medical sciences | Myocarditis. Cardiomyopathies | Medical sciences | Coronary heart disease | Recombinant Proteins - therapeutic use | Recurrence | Myocardial Infarction - mortality | Humans | Immunoglobulin Fab Fragments - adverse effects | Middle Aged | Thrombin - antagonists & inhibitors | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Heparin - therapeutic use | Male | Immunoglobulin Fab Fragments - therapeutic use | Recombinant Proteins - adverse effects | Heparin - adverse effects | Angioplasty, Balloon, Coronary | Myocardial Infarction - therapy | Adult | Female | Drug Therapy, Combination | Double-Blind Method | Angina Pectoris - drug therapy | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Myocardial Infarction - drug therapy | Hirudins - adverse effects | Aged | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Hemorrhage - chemically induced | Abciximab | Drug utilization | Bivalirudin | Heparin | Comparative analysis | Drug therapy | Heart attack | Myocardial infarction | Heart attacks | Monoclonal antibodies | Biomarkers | Death | Acute coronary syndromes | Bleeding | Manuscripts | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
by Wiviott, Stephen D and Braunwald, Eugene and McCabe, Carolyn H and Montalescot, Gilles and Ruzyllo, Witold and Gottlieb, Shmuel and Neumann, Franz-Joseph and Ardissino, Diego and De Servi, Stefano and Murphy, Sabina A and Riesmeyer, Jeffrey and Weerakkody, Govinda and Gibson, C. Michael and Antman, Elliott M and TRITON TIMI 38 Investigators and TRITON-TIMI 38 Investigators
The New England journal of medicine, ISSN 0028-4793, 11/2007, Volume 357, Issue 20, pp. 2001 - 2015
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cardiology. Vascular system | Heart | Biological and medical sciences | General aspects | Medical sciences | Coronary heart disease | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Myocardial Infarction - epidemiology | Thiophenes - adverse effects | Ticlopidine - therapeutic use | Humans | Middle Aged | Acute Coronary Syndrome - mortality | Male | Angioplasty, Balloon, Coronary - adverse effects | Ticlopidine - adverse effects | Female | Stroke - epidemiology | Aspirin - therapeutic use | Thrombosis - prevention & control | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Double-Blind Method | Kaplan-Meier Estimate | Purinergic P2 Receptor Antagonists | Piperazines - therapeutic use | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Acute Coronary Syndrome - drug therapy | Prodrugs - adverse effects | Acute Coronary Syndrome - therapy | Aged | Myocardial Infarction - prevention & control | Prodrugs - therapeutic use | Hemorrhage - chemically induced | Complications and side effects | Clopidogrel | Dosage and administration | Drug therapy | Cardiovascular disease | Heart attacks | Angina pectoris | Acute coronary syndromes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights